My peep.
It speaks volumes about JCRs belief in the product based on their experience with it. They have seen it works enough to want to expand it out of the hospitals the clinical trials were done in. Also enough to enter into a alliance with Medipal to enable them to do it. "....effectively leveraging MEDIPAL’s strengths in distribution and sales promotion and JCR’s strengths in pharmaceutical research and development." That should lead to more royalties for Mesoblast.
The alliance is to discussing a joint venture to expand their business to the USA. Neither document from either company mentions Mesoblast or Temcell in relation to the USA expansion. The only detail is in the Medipal document; http://v4.eir-parts.net/v4Contents/View.aspx?template=announcement&sid=38002&code=7459
That only discusses moving forward with two JCR candidates for FDA testing.
However, the deal with Malinkrodt giving them exclusive world wide rights to everywhere but Japan and China has expired. Then we have a possible joint venture in to the USA of a business whose principals have good tidings about Temcell.
Will that add something into the mix re the aGVHD product in the USA, no idea. The FDA had enough evidence to have give the product Fast Track status in early March 2017. My guess is we will find out when a partnership is announced rather than if.
MSB Price at posting:
$1.34 Sentiment: Buy Disclosure: Held
(20min delay)
